BA
PCRX icon

BlackRock Advisors’s Pacira BioSciences PCRX Stock Holding History

BlackRock Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.25M Sell
131,453
-178,828
-58% -$5.97M ﹤0.01% 1204
2016
Q3 		$10.6M Buy
310,281
+263,943
+570% +$10.3M 0.01% 837
2016
Q2 		$1.56M Buy
46,338
+20,722
+81% +$1.02M ﹤0.01% 1553
2016
Q1 		$1.36M Sell
25,616
-140,382
-85% -$8.21M ﹤0.01% 1609
2015
Q4 		$12.7M Sell
165,998
-6,657
-4% -$377K 0.01% 711
2015
Q3 		$7.1M Sell
172,655
-4,529
-3% -$277K 0.01% 945
2015
Q2 		$12.5M Buy
177,184
+127,169
+254% +$10M 0.01% 688
2015
Q1 		$4.44M Sell
50,015
-31,602
-39% -$3.21M ﹤0.01% 1003
2014
Q4 		$7.24M Sell
81,617
-1,704
-2% -$161K 0.01% 869
2014
Q3 		$8.07M Buy
83,321
+62,631
+303% +$6.09M 0.01% 843
2014
Q2 		$1.9M Buy
20,690
+64
+0.3% +$4.87K ﹤0.01% 1190
2014
Q1 		$1.44M Buy
20,626
+1,825
+10% +$124K ﹤0.01% 1315
2013
Q4 		$1.08M Buy
18,801
+1,205
+7% +$63.4K ﹤0.01% 1467
2013
Q3 		$846K Buy
17,596
+5,050
+40% +$184K ﹤0.01% 1524
2013
Q2 		$364K Buy
+12,546
New +$363K ﹤0.01% 2064

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlackRock Advisors's PCRX Position: Q4 2016 in Review

BlackRock Advisors reduced its Pacira BioSciences (PCRX) stake by 58% in Q4 2016, selling an estimated $5.97M and leaving 131,453 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

BlackRock Advisors first reported a position in PCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $12.7M in Q4 2015. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • BlackRock Advisors held 131,453 shares of Pacira BioSciences worth $4.25M as of Q4 2016.
  • BlackRock Advisors sold 178,828 Pacira BioSciences shares in Q4 2016, an estimated $5.97M.
  • Pacira BioSciences made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1204 holding.
  • BlackRock Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Pacira BioSciences position peaked at $12.7M in Q4 2015.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.